In a bid to bolster its oncology portfolio, Genmab has agreed to acquire ProfoundBio in an all-cash transaction for a total of US$1.8 B. Through the deal, Genmab picks up worldwide rights to three of ProfoundBio’s candidates currently in clinical development, including rinatabart sesutecan (Rina-S), a next-generation, potential best-in-class Topo1 antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumours. With Genmab’s lead asset Darzalex (daratumumab) set to face patent expiry in 2029, the takeover marks a significant move by the company to secure future revenue generators.